Skip to main content

Advertisement

Table 2 IOP (mm Hg) in both groups

From: Efficacy of intravitreal ranibizumab combined with Ahmed glaucoma valve implantation for the treatment of neovascular glaucoma

  Pre-surgery 2 weeks 1 month 3 months 6 months 12 months
Injection Group IOP (mean ± SD) 46.4 ± 13.3 14.5 ± 4.4 16.9 ± 4.2 18.1 ± 3.8 20.5 ± 4.5 21.1 ± 4.2
(Minimum - Maximum) (24.5–76.0) (6.5–24.0) (9.0–26.0) (10.0–24.0) (14.0–28.0) (15.5–28.0)
Control Group IOP (mean ± SD) 45.0 ± 14.9 15.6 ± 5.6 17.1 ± 5.3 19.4 ± 5.0 20.2 ± 3.9 22.1 ± 4.7
(Minimum - Maximum) (23.5–78.5) (6.0–27.5) (8.0–28.0) (12.0–31.5) (14.5–27.0) (12.0–30.0)
P 0.74 0.51 0.85 0.35 0.83 0.53
  1. Note: IOPs before surgery and at two weeks, one month, three months, six months and 12 months after surgery were determined using an applanation tonometer (mean of 9 am and 4 pm measurements). Differences in IOPs at various time points throughout follow-up were compared between the two groups using the t test